Like with CRS, alternative monoclonal antibodies that have been used to manage neurotoxicity include siltuximab, a chimeric monoclonal antibody that directly binds IL-6, and Anakinra, a recombinant IL-1 receptor antagonist [4,86,87]. The gene discussed is IL6; the disease is congenital rubella syndrome.